A targeted sequencing of 72 prostate cancer driver genes in the plasma cell-free DNA of patients with mCRPC revealed 37 somatic mutations mapped to FOXA1 3′ UTR in 34/290 (12%) of the patients (Fig. 3) (Annala et al. 2018). This evidence concerns the gene FOXA1 and prostate cancer.